Efficacy and Safety of Kleeb Bua Daeng Formula in Mild Cognitive Impairment Patients: A Phase I Randomized, Double-Blind, Placebo-Controlled Trial

Table 2

Baseline characteristics of the KBD clinical trial for education, underlying diseases, average pill count, and MoCA mean score.

	KBD	Placebo	value
Education (mean ± SD) (years)	11.65 ± 5.20	10.35 ± 5.06	0.4281
Min	4	4
Max	18	18
Underlying diseases
Noninsulin-dependent	2	1
Disorder of lipoprotein	3	2
Heart disease	1	0
Hypertension	4	2
Gonarthrosis	0	1
Functional dyspepsia	1	1
Panic disorder	0	1
Hyperplasia of prostate	0	1
Average pill count capsules/month (mean ± SD)	111.7 ± 8.81	114.27 ± 7.82	0.100
MoCA score (mean ± SD)	21.55 ± 1.70	21.75 ± 1.59	0.703
Min	19	19
Max	24	24